Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators against 354 Molecularly Identified Aspergillus Isolates

Management of superficial aspergillosis is
a major challenge owing to the frequent relapses and
treatment failure, which may pose a potential risk,
thereby gradually developing resistant species. There-
fore, necessitating the development of new antifungals
with higher potency should be considered as alterna-
tive strategies for efficient management of infections.
We aimed to investigate the susceptibility of
Aspergillus isolates toward a novel triazole, efina-
conazole, in comparison with various classes of
antifungal drugs. Antifungal susceptibility testing
was performed according to the Clinical and Labora-
tory Standards Institute M38-A2 guidelines. Efina-
conazole exhibited poor activity against mutant A.
fumigatus strains, A. niger sensu stricto, and A.
tubingensis with GM MIC values of 3.62, 1.62, and
2 lg/ml, respectively; however, surprisingly, it effi-
ciently inhibited the growth of A. terreus sensu stricto,